Graduate Student Kirsten Xuewen Chen speaking with Gladstone Investigator Isha Jain

A new study from Gladstone researchers, including first author Kirsten Xuewen Chen (right), sheds light on the molecular workings at play when oxygen exceeds normal levels, with findings that may one day inform the decision to use supplemental oxygen as a medical treatment.


It only takes holding your breath for slightly too long to understand that too little oxygen is bad for you. But can you also have too much? Indeed, breathing air with a higher oxygen level than your body needs can cause health problems or even death.

But with scant research on the topic, scientists have known little about how the body senses too much oxygen. Now, a new study from Gladstone Institutes has greatly expanded the scientific body of knowledge about the mechanisms at play, and why it matters for health.

Their findings, reported in the journal Science Advances, explain how breathing air with different levels of oxygen—from too little, to just right, or too much—affects the creation and degradation of different proteins in the lungs, heart, and brain of mice. Notably, the study also highlights a particular protein that may play a central role in regulating how cells respond to hyperoxia.

“These results have implications for many different diseases,” says Gladstone Assistant Investigator Isha Jain, PhD, senior author of the new study. “More than 1 million people in the US breathe supplemental oxygen every day for medical reasons, and studies suggest it could be making things worse in some cases. That’s just one setting where our work is starting to explain what’s happening and how the body responds.”

Understanding Oxygen’s Effects

Most prior research on oxygen levels has examined the molecular effects of too little oxygen. And even in that realm, most of the focus has been on how low oxygen affects which genes are turned on or off.

Gladstone Investigator Isha Jain speaking with graduate student Kirsten Xuewen Chen

Isha Jain (left) is senior author of the new study published in Science Advances.

“Our study enters uncharted territory by using mice and looking downstream of gene expression at which proteins abnormally accumulate or degrade in response to different oxygen concentrations,” says Kirsten Xuewen Chen, first author of the new paper and a graduate student at UC San Francisco.

The research builds on the team’s prior work, which revealed that in response to too much oxygen, certain proteins containing iron and sulfur clusters become degraded, leading cells to malfunction.

“Now, we wanted to get a more dynamic picture of how proteins are regulated when oxygen levels are too high or too low,” Chen says.

To do so, the team exposed mice for several weeks to air with oxygen level of 8 percent, 21 percent (the usual level we breathe in Earth’s atmosphere), or 60 percent. Meanwhile, they gave the mice food containing a distinct form of nitrogen that the animals’ bodies incorporated into new proteins. This nitrogen isotope acted as a “label” that enabled the researchers to calculate protein turnover rates—the balance between protein synthesis and degradation—for thousands of different proteins in the lungs, heart, and brain.

“We’re grateful to our collaborators who are the experts in this technique, known as stable isotope labeling of amino acids in mice,” Jain says. “Without it, we could not have done this study.”

A Key Protein Builds Up

The researchers found that oxygen levels more dramatically affected proteins in the lungs of mice than the heart or brain. They identified certain proteins with abnormal turnover rates under high- or low-oxygen conditions.

Gladstone Investigator speaking with graduate student Kirsten Xuewen Chen

The findings from the team, which includes Isha Jain (left) and Kirsten Xuewen Chen (right), could be used one day to inform when to use supplemental oxygen as a medical treatment.  

One particular protein that accumulated in high-oxygen conditions, MYBBP1A, piqued their attention. MYBBP1A is a transcription regulator, meaning it directly affects gene expression.

“This caught our eye because prior research has shown that other transcription factors called hypoxia-inducible factors, or HIFs, play a big role in cells’ response to low oxygen,” Chen says. “Our work nominates MYBBP1A for a related role in hyperoxia signaling.”

MYBBP1A is involved in the production of ribosomes—cellular “machines” that build proteins. Further experiments surfaced clues that, in response to high oxygen levels, accumulation of this protein in the lungs may affect production of ribosomal RNA, a key component of ribosomes.

Jain’s team is now examining the precise molecular role of MYBBP1A during hyperoxia, including whether its response is protective or harmful. This work could set the stage for novel treatments that target the MYBBP1A protein or associated molecules in ways that counter the bad effects of hyperoxia—similar to widespread research efforts targeting HIF proteins in low-oxygen conditions.

First-of-Its-Kind Dataset

The new study presents a first-of-its kind dataset of protein turnover rates in different tissues of mice exposed to different oxygen levels. The team hopes its results will inspire other researchers to further investigate the effects of too much or too little oxygen on the body, which could transform the way we treat disease.

For Media

Kelly Quigley
Director, Science Communications and Media Relations

About the Study

The paper “In Vivo Protein Turnover Rates in Varying Oxygen Tensions Nominate MYBBP1A as a Novel Mediator of the Hyperoxia Response” was published in the journal Science Advances on December 8, 2023.

In addition to Jain and Chen, other authors of the study are: Augustinus Haribowo, Alan Baik, Andrea Fossati, Erica Stevenson, Michela Traglia, Alexander Pico, and Danielle Swaney of Gladstone; Yiwen Chen and Daniel Jarosz of Stanford University; Nabora Reyes, Tien Peng, Michael Matthay, and Abigail Buchwalter of UC San Francisco; and Sina Ghaemmaghami of the University of Rochester.

This work was supported by the American Heart Association, the California Institute for Regenerative Medicine, the National Institutes of Health (T32-HL007731, NIH DP5 DP5OD026398), the Chan Zuckerberg Biohub, the Sarnoff Cardiovascular Research Foundation, the UCSF Program for Breakthrough Biomedical Research, the Tobacco-Related Disease Research Program, and a gift from Dave Wentz.


About Gladstone Institutes

Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.

Featured Experts

Support Discovery Science

Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.

Donate Now